FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

09/18/14 - 20140271619 - Cd20 conformational isomers and methods of using
Described herein are methods of screening for compounds that bind to conformational isomers of CD20 polypeptides. Also described are antibodies that bind to conformational isomers of CD20 polypeptides....

09/18/14 - 20140271620 - Modified hyaluronan and uses thereof in cancer treatment
Uses of depolymerized hyaluronan (e.g., prepared by sonicating high molecular weight hyaluronan such as naturally-occurring hyaluronan) or anti-Hyal-2 antibody in cancer treatment. Also described herein are methods for preparing depolymerized and crosslinked hyaluronan by sonication and the hyaluronan composition thus obtained....

09/18/14 - 20140271621 - Methods of prognosis and diagnosis of pancreatic cancer
Disclosed herein are methods of diagnosing pancreatic cancer in a patient by detecting the presence and/or amount of at least three biomarkers of pancreatic cancer in a sample from the patient. The methods and biomarkers may be used to develop an accurate prognosis for a patient having cancer or suspected...

09/18/14 - 20140271622 - Methods of cell culture
Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using copper, are described....

09/18/14 - 20140271623 - Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described....

09/18/14 - 20140271624 - Anti-notch nrr antibodies and methods using same
The invention provides anti-Notch1 NRR antibodies, and compositions comprising and methods of using these antibodies....

09/18/14 - 20140271625 - Methods for treating bleeding disorders
Disclosed are methods for treating bleeding disorders, such as hemophilia, in subjects in need thereof by administering an antibody that specifically binds CD73. The methods reduce production of adenosine, increase platelet activation and/or enhance the level of coagulation on the platelet surface to reduce and/or stop bleeding. In some embodiments,...

09/18/14 - 20140271626 - Mutated anti-tnfa antibodies and methods of their use
The present invention is directed to modified antibodies, including anti-TNFα antibodies, in which C-terminal amino acids of heavy chain sequences are modified from a native sequence of proline-glycine-lysine (“PGK”) to one that includes a proline positioned between the glycine and lysine, resulting in a C-terminal sequence of proline-glycine-proline-lycine (“PGPK”). The...

09/18/14 - 20140271627 - Humanized, anti-n2 antibodies
The present invention encompasses humanized antibodies that specifically bind N2 peptide, methods for the preparation thereof and methods for the use thereof....

09/18/14 - 20140271628 - Humanized, anti-n2 antibodies
The present invention encompasses humanized antibodies that specifically bind N2 peptide, methods for the preparation thereof and methods for the use thereof....

09/18/14 - 20140271629 - Chrdl-1 antigen binding proteins and methods of treatment
The present invention provides compositions and methods relating to or derived from antigen binding proteins to CHRDL-1. Human, humanized, and chimeric antibodies, as well as fragments and derivatives thereof are further contemplated. Other embodiments include nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, as well as...

09/18/14 - 20140271630 - Rituximab induction therapy followed by glatiramer acetate therapy
The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject,...

09/18/14 - 20140271631 - Assay for predictive biomarkers
The present invention provides assays for detecting presence or quantity of multiple biomarkers in one biological sample....

09/18/14 - 20140271632 - Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
The present invention relates to the field of protein production, and in particular to methods and compositions for modulating glycosylation of proteins expressed in host cells....

09/18/14 - 20140271633 - Mammalian cell culture performance through surfactant supplementation of feed media
The present invention provides methods for increasing cell culture performance through the use of chemically defined feed media (CDFM). In particular, the present invention provides methods for the use of surfactants as supplements to CDFM to allow for higher concentrations of media components and thereby result in increased cell culture...

09/18/14 - 20140271634 - Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
The invention provides combinations comprising a MEK inhibitor (such as GDC-0973 or GDC-0623), or a pharmaceutically acceptable salt thereof and a HER3/EGFR inhibitor (such as MEHD7945A). The combinations are particularly useful for treating hyperproliferative disorders, such as cancer....

09/18/14 - 20140271635 - Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell...

09/18/14 - 20140271636 - Formulation of an antibody and use thereof
The present invention provides a method for preparation of a lyophilized formulation of an anti-CD 20 antibody as well as to a lyophilized formulation of an anti-CD 20 antibody, comprising an anti-CD 20 antibody and having a residual moisture content in the range of 1% to 10%. The present invention...

09/18/14 - 20140271637 - Methods of administering anti-tnfalpha antibodies
Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g.,...

09/18/14 - 20140271638 - Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas
Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical...

09/18/14 - 20140271639 - Semaphorin 7a induced lung fibrogenesis occurs in a cd-4-dependent, macrophage dependent manner
The present invention provides methods of treating a mammal diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the mammal a compound or composition which modulates a target, such as Cofilin-1 and/or Plexin C1. The method of the invention...

09/11/14 - 20140255388 - Toll like receptor 3 antagonists, methods and uses
Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists or fragments, and methods of making and using the foregoing are disclosed....

09/11/14 - 20140255389 - Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung...

09/11/14 - 20140255390 - Method of treating rheumatoid arthritis with an anti-il-6r antibody
The present invention provides methods of preventing or treating rheumatoid arthritis using a fully human antibody or antigen-binding fragment thereof that specifically binds human interleukin-6 receptor (hIL-6R). The methods of the present invention may include administration of a second therapeutic agent, such as one or more of a non-steroidal anti-inflammatory...

09/11/14 - 20140255391 - Methods for the treatment of il-1beta related diseases
Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof....

09/11/14 - 20140255392 - Substituted imidazopyridines and intermediates thereof
The present invention relates to substituted imidazopyridine compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition...

09/11/14 - 20140255393 - Compositions and methods for autoimmune disease
Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (SCNP), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease....

09/11/14 - 20140255394 - Method of treating colorectal cancer
The present invention relates to the use of certain platinum compounds including [PtCl2(cis-1,4-diaminocyclohexane)], or combinations of these compounds with a variety of other agents for treating and/or preventing the progression of colorectal cancer in mammals. In particular, the invention provides methods of treating and/or preventing oxaliplatin-refractory colorectal cancer in mammals....

09/11/14 - 20140255395 - Complement inhibition for improved nerve regeneration
The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration...

09/11/14 - 20140255396 - Multiple-variable dose regimen for treating tnfalpha-related disorders
Multiple-variable dose methods for treating TNFα-related disorders, including Crohn's disease and psoriasis, comprising administering TNFα inhibitors, including TNFα antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor...

09/11/14 - 20140255397 - Methods and compositions for modulation of blood-neural barrier
Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway....

09/11/14 - 20140255398 - Antigen-binding molecule inducing immune response to target antigen
The present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are...

09/11/14 - 20140255399 - Separation method for fucosylated antibodies
The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to Fc receptors. The invention further relates to the use of Fc receptors for the separation of antibodies having different degrees of...

09/04/14 - 20140248262 - Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer....

09/04/14 - 20140248263 - Bisphenol compounds and methods for their use
Compounds having a structure of Formula I: wherein G, a, Q, L2, R1, R2, R3, R4, R5 and R6 are as defined herein are provided. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided....

09/04/14 - 20140248264 - Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
Methods and compositions relating to TIC10 are described according to aspects of the present invention. The compositions and methods have utility in treating disease, particularly cancer in a subject in need thereof, including a human subject as well as subjects of other species. The compositions have utility in treating brain...

09/04/14 - 20140248265 - Therapeutic antibodies binding il 12rbeta1
The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of...

09/04/14 - 20140248266 - Anti-cd40 antibody mutants
A mutant of a potentially therapeutic anti-CD40 antibody is provided which mutant has reduced ADCC and CDC activities designed to be optimized as a pharmaceutical agent. A mutant of an agonistic anti-CD40 antibody, comprising mutation and/or substitution of at least one amino acid in the constant region to reduce the...

09/04/14 - 20140248267 - Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in...

09/04/14 - 20140248268 - Rab7 gtpase inhibitors and related methods of treatment
This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or...

08/28/14 - 20140242069 - Krt19 stabilizing her2 and use thereof
Provided is a method of decreasing the stability of HER2 (human epidermal growth factor receptor 2) in a cell or individual comprising administering an effective amount of an expression or activity inhibitor of KRT19 (cytokeratin 19) to the cell or individual....

08/28/14 - 20140242070 - Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
Disclosed herein are methods of treating cancer in a subject, and methods for inhibiting growth, migration and/or invasion of a cancer cell in the subject, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that downmodulates Fzd2. The antibody may specifically bind...

08/28/14 - 20140242071 - M-csf specific monoclonal antibody and uses thereof
M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease....

08/28/14 - 20140242072 - Anti-icam-1 antibodies to treat multiple-myeloma related disorders
The invention relates to the use of an antibody or an antigen-binding fragment thereof with binding specificity for ICAM-1, or a variant, fusion or derivative of said antibody or an antigen-binding fragment with binding specificity for ICAM-1, for the treatment of a multiple-myeloma-related disorder. The invention also relates to methods...

08/21/14 - 20140234295 - Isoflavonoid compounds and methods for the treatment of cancer
Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions....

08/21/14 - 20140234296 - Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
The present invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. The present invention further provides methods for treating various cancers and chronic infections with stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof....

08/21/14 - 20140234297 - Antibody constant domain regions and uses thereof
The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically...

08/21/14 - 20140234298 - Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof
The present disclosure describes a pharmaceutical combination of an anti-CD20 antibody and an anti-GM-CSF antibody. Said combinations are highly efficacious in the treatment of B cell malignancies and inflammatory disorders....

08/21/14 - 20140234299 - Therapies for chronic renal failure using one or more integrin antagonists
The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects in, or at risk of chronic renal failure, or at risk of a need for renal replacement therapy. The methods involve the administration of certain integrin antagonists....

08/21/14 - 20140234300 - Method of modulating the activity of functional immune molecules
The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity....

08/21/14 - 20140234301 - Modulation of pilr to treat immune disorders
The present invention provides methods of using PILRα agonists, or PILRβ antagonists, to treat immune disorders, such as autoimmune and inflammatory disorders, including CNS, joint and gut inflammation....

08/21/14 - 20140234302 - Methods and compositions for reducing amyloid beta levels
The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for...

08/21/14 - 20140234303 - Treatment of neurological conditions
The present invention is directed to a method for treating an inflammatory neurodegenerative condition of the CNS in a subject comprising administering to said subject a G-CSF or G-CSFR inhibiting agent selected from the group consisting of an antibody specific for G-CSF, a soluble G-CSFR or a G-CSF-binding portion thereof...

08/21/14 - 20140234304 - Human tissue factor antibody and uses thereof
The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions,...

08/21/14 - 20140234305 - Methods of treatment using bevacizumab
Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-VEGF agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of VEGF signaling), or a combination therapy that includes co-administering an anti-VEGF agent, with an...

08/21/14 - 20140234306 - Agent and method for reducing inflammatory markers
A method for treating an autism spectrum condition includes administering an effective dose of a TNF-α inhibiting agent to a person having an autism spectrum condition or pervasive development disorder and at least one of elevated TNF-α in the cerebrospinal fluid or elevated TNF-α in the serum, as compared to...

08/21/14 - 20140234307 - Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
Described herein are methods of treating multiple sclerosis (MS), such as secondary progressive MS (SPMS), by intrathecally administering a B cell depleting agent, such as rituximab, alone or in combination with intravenous administration of a B cell depleting agent. Also described is the use of IL-12p40, CXCL13, or both as...

08/21/14 - 20140234308 - Treatment of breast cancer with companion diagnostic
Despite advances in therapy, breast cancer remains the most common malignancy in women. Of particular concern is the aggressive triple negative subtype that lacks the BRCA1 mutation, estrogen receptor, and epidermal growth factor type 2 receptor (Her-2/neu), which accounts for approximately half of all breast cancer deaths. Provided herein are...